enVVeno Medical cuts Q2 net loss by 46% on cost discipline

2 min read | Published on 31 Jul 2026, 06:43 PM |Updated on 31 Jul 2026, 06:53 PM

Reviewed by

Shriram SScanX News Team

Key Highlights

enVVeno Medical cut its Q2 net loss by 46% to $3.6M, with EPS improving to $(5.37). The company secured FDA IDE approval for its pivotal TAVVE study and holds $21.5M in cash, funding operations through Q3 2027.

*this image is generated using AI for illustrative purposes only.

enVVeno Medical Corporation (NASDAQ: NVNO) reported a net loss of $3.6 million for the second quarter ended June 30, 2026, a 46% improvement from the $6.7 million loss in the same period last year. The reduction in losses coincides with a pivotal regulatory milestone: the U.S. Food and Drug Administration (FDA) granted Investigational Device Exemption (IDE) approval for the TAVVE pivotal study. This approval enables patient enrollment for the enVVe System, a first-in-class non-surgical venous valve replacement, positioning the company to address severe chronic venous insufficiency in approximately 3 million U.S. patients.

Basic and diluted net loss per share narrowed to $5.37, down from $11.52 in the second quarter of 2025. This represents a 53% year-over-year decrease in per-share losses, reflecting disciplined capital management during a phase of clinical advancement. Rob Berman, Chief Executive Officer of enVVeno Medical, described the quarter as a defining milestone that allows the company to proceed with the pivotal study aimed at changing treatment trajectories for patients lacking effective options.

The company ended the quarter with total cash and investments of $21.5 million, comprising $2.8 million in cash and cash equivalents and $18.7 million in short-term investments. Management stated this liquidity is sufficient to fund operations into the third quarter of 2027. Cash burn for the second quarter was $3.4 million, consistent with the projected range of $3 million to $4 million per quarter.

Financial Performance Summary

Metric	Q2 2026	Q2 2025	Change
Net Loss	$3.6 million	$6.7 million	46% decrease
Net Loss Per Share (Basic/Diluted)	$5.37	$11.52	53% decrease
Cash and Investments	$21.5 million	N/A	N/A
Cash Burn	$3.4 million	N/A	N/A

What the Numbers Show

The significant contraction in net loss underscores enVVeno Medical’s ability to control expenses while advancing its clinical pipeline. With revenue remaining negligible as a late-stage device developer, cash preservation is the primary financial metric. The current runway into Q3 2027 aligns with the expected timeline for the TAVVE pivotal trial, which aims to enroll up to 230 patients across 40 U.S. sites. Although cash burn is expected to rise to $4–$5 million per quarter in the second half of 2026 due to study initiation, the existing capital base mitigates immediate dilution risk, allowing management to focus on site activation and enrollment.

How might the anticipated increase in quarterly cash burn to $4–$5 million impact enVVeno Medical's runway if patient enrollment in the TAVVE study faces delays?

What are the potential regulatory or clinical hurdles that could arise during the TAVVE pivotal study involving 230 patients across 40 U.S. sites?

Given the current cash position, what are the likely scenarios for capital raising strategies before Q3 2027 to support post-approval commercialization?